Quarterly report pursuant to Section 13 or 15(d)

REVENUES FROM CONTRACTS AND SIGNIFICANT CUSTOMERS

v3.21.2
REVENUES FROM CONTRACTS AND SIGNIFICANT CUSTOMERS
 9 Months Ended
Sep. 30, 2021
REVENUES FROM CONTRACTS AND SIGNIFICANT CUSTOMERS  
REVENUES FROM CONTRACTS AND SIGNIFICANT CUSTOMERS

NOTE 16. REVENUES FROM CONTRACTS AND SIGNIFICANT CUSTOMERS

Disaggregation of Net Revenues

The Company has the following marketed products, Qbrexza®, Accutane®, Targadox®, Ximino®, Exelderm®, Luxamend® and Ceracade®. Substantially all of the Company’s product revenues are recorded in the U.S. Revenues by product are summarized as follows (dollars in thousands):

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

    

Three months ended September 30, 

    

Nine Months Ended September 30, 

​

    

2021

    

2020

    

2021

    

2020

Revenue

​

​

  

​

​

  

​

​

  

​

​

  

Targadox®

​

$

5,184

​

$

7,214

​

$

18,110

​

$

22,195

Ximino®

​

 

2,864

​

 

1,031

​

 

6,277

​

 

5,854

Exelderm®

​

 

1,366

​

 

1,226

​

 

4,319

​

 

2,913

Accutane®

​

 

3,531

​

 

—

​

 

5,672

​

 

—

Qbrexa®

​

 

6,636

​

 

—

​

 

11,204

​

 

—

Other branded revenue

​

 

29

​

 

(24)

​

 

35

​

 

(154)

Total Product revenue, net

​

$

19,610

​

$

9,447

​

$

45,617

​

$

30,808

​

Significant Customers

For the three months ended September 30, 2021, one of the Company’s customers accounted for more than 10% of its total gross product revenue. For the nine months ended September 30, 2021, none of the Company’s customers accounted for more than 10% of its total gross product revenue

As of September 30, 2021, two of the Company’s customers accounted for more than 10% of its total accounts receivable balance at 20.7% and 14.9%.